Literature DB >> 372242

Recovery of endothelial cell prostacyclin production after inhibition by low doses of aspirin.

E A Jaffe, B B Weksler.   

Abstract

Endothelial cells synthesize prostacyclin (PGI(2)), an unstable prostaglandin that inhibits platelet aggregation and serotonin release. Because cyclooxygenase, which is necessary for synthesis of PGI(2), is inactivated by aspirin, we examined the effect of aspirin on PGI(2) production by cultured human endothelial cells. Endothelial cells synthesize PGI(2) (20.1+/-7.2 ng/10(6) cells, mean+/-SD) when stimulated with 20 muM sodium arachidonate for 2 min. PGI(2) production is inhibited by low-dose aspirin (5 muM); the t((1/2)) of inactivation is 6.0+/-1.3 min (mean+/-SEM, n = 3). Thus, endothelial cell cyclooxygenase is as sensitive to aspirin as the enzyme in platelets. After 1 h incubation with aspirin, endothelial cell PGI(2) production was inhibited 50% by 2.1+/-0.4 muM aspirin and was inhibited 90% by 6.2+/-0.9 muM aspirin (mean+/-SEM, n = 4). When endothelial cells were incubated with 100 muM aspirin, washed, and recultured, their ability to synthesize PGI(2) returned to control levels in 35.6+/-1.0 h (mean+/-SEM, n = 4). Recovery of endothelial PGI(2) production after aspirin depended on de novo protein synthesis because treatment with cycloheximide (3 mug/ml) inhibited recovery by 92%.These results indicate that although endothelial cell cyclooxygenase in vitro is inhibited by low concentrations of aspirin, endothelial cells rapidly resynthesize their cyclooxygenase after the aspirin is removed. This rapid resynthesis of cyclooxygenase lessens the likelihood that aspirin used in clinical doses promotes thrombosis.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 372242      PMCID: PMC371983          DOI: 10.1172/JCI109332

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  13 in total

1.  Cultured human skin fibroblasts and arterial cells produce a labile platelet-inhibitory prostaglandin.

Authors:  N L Baenziger; M J Dillender; P W Majerus
Journal:  Biochem Biophys Res Commun       Date:  1977-09-09       Impact factor: 3.575

Review 2.  Unstable metabolites of arachidonic acid and their role in haemostasis and thrombosis.

Authors:  S Moncada; J R Vane
Journal:  Br Med Bull       Date:  1978-05       Impact factor: 4.291

3.  Aspirin, thromboxane, and prostacyclin in rats: A dilemma resolved?

Authors:  M Livio; S Villa; G de Gaetano
Journal:  Lancet       Date:  1978-06-17       Impact factor: 79.321

4.  Thrombogenic effect of high-dose aspirin in rabbits. Relationship to inhibition of vessel wall synthesis of prostaglandin I2-like activity.

Authors:  J G Kelton; J Hirsh; C J Carter; M R Buchanan
Journal:  J Clin Invest       Date:  1978-10       Impact factor: 14.808

5.  Modulation of human platelet adenylate cyclase by prostacyclin (PGX).

Authors:  R R Gorman; S Bunting; O V Miller
Journal:  Prostaglandins       Date:  1977-03

6.  Effects of prostacyclin (PGX) on cyclic AMP concentrations in human platelets.

Authors:  J E Tateson; S Moncada; J R Vane
Journal:  Prostaglandins       Date:  1977-03

7.  Stimulation of endothelial cell prostacyclin production by thrombin, trypsin, and the ionophore A 23187.

Authors:  B B Weksler; C W Ley; E A Jaffe
Journal:  J Clin Invest       Date:  1978-11       Impact factor: 14.808

8.  Effect of prostacyclin (PGI2) on platelet adhesion to rabbit arterial subendothelium.

Authors:  E A Higgs; S Moncada; J R Vane; J P Caen; H Michel; G Tobelem
Journal:  Prostaglandins       Date:  1978-07

9.  Synthesis of prostaglandin I2 (prostacyclin) by cultured human and bovine endothelial cells.

Authors:  B B Weksler; A J Marcus; E A Jaffe
Journal:  Proc Natl Acad Sci U S A       Date:  1977-09       Impact factor: 11.205

10.  Inhibition of platelet prostaglandin synthetase by oral aspirin.

Authors:  J W Burch; N Stanford; P W Majerus
Journal:  J Clin Invest       Date:  1978-02       Impact factor: 14.808

View more
  39 in total

Review 1.  Aspirin in patients with coronary artery disease: is it simply irresistible?

Authors:  G V Nair; C J Davis; M E McKenzie; D R Lowry; V L Serebruany
Journal:  J Thromb Thrombolysis       Date:  2001-04       Impact factor: 2.300

2.  [Significance of the endothelium of the vascular wall for maintaining hemostasis].

Authors:  U Delvos; G Müller-Berghaus
Journal:  Klin Wochenschr       Date:  1985-12-16

3.  Aspirin inhibits expression of sFLT1 from human cytotrophoblasts induced by hypoxia, via cyclo-oxygenase 1.

Authors:  C Li; N S Raikwar; M K Santillan; D A Santillan; C P Thomas
Journal:  Placenta       Date:  2015-01-17       Impact factor: 3.481

4.  Unidirectional transfer of prostaglandin endoperoxides between platelets and endothelial cells.

Authors:  A I Schafer; D D Crawford; M A Gimbrone
Journal:  J Clin Invest       Date:  1984-04       Impact factor: 14.808

5.  Arachidonic acid metabolites, hypertension and arteriosclerosis.

Authors:  P C Weber; W Siess; B Scherer; E Held; H Witzgall; R Lorenz
Journal:  Klin Wochenschr       Date:  1982-05-17

6.  Effect of hematin on endothelial cells and endothelial cell-platelet interactions.

Authors:  S M Neely; D V Gardner; D Green; C H Ts'ao
Journal:  Am J Pathol       Date:  1984-06       Impact factor: 4.307

7.  A clinical trial of a slow-release formulation of acetylsalicylic acid in patients at risk for preeclampsia.

Authors:  J Shen; S Wanwimolruk; P D Wilson; R J Seddon; M S Roberts
Journal:  Br J Clin Pharmacol       Date:  1993-06       Impact factor: 4.335

8.  Aspirin decreases platelet uptake on Dacron vascular grafts in baboons.

Authors:  W C Mackey; R J Connolly; A D Callow; E M Keough; K Ramberg-Laskaris; J L McCullough; T F O'Donnell; A Melaragno; C R Valeri; B Weiblen
Journal:  Ann Surg       Date:  1984-07       Impact factor: 12.969

9.  Aspirin inhibits vascular plasminogen activator activity in vivo. Studies utilizing a new assay to quantify plasminogen activator activity.

Authors:  R I Levin; P C Harpel; D Weil; T S Chang; D B Rifkin
Journal:  J Clin Invest       Date:  1984-08       Impact factor: 14.808

10.  The evolution of non-steroidal anti-inflammatory drugs and their mechanisms of action.

Authors:  J Vane
Journal:  Drugs       Date:  1987       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.